FUNCTIONAL BRANDS INC.
MEHA · Healthcare · $103811 mkt cap · FY2025 filings · Narrow moat ·
Wonderful & reasonably priced
The five investor questions
2024–2025: revenue 6566455.00 to 6611484.00, increasing; diluted EPS -0.08 to 0.01, increasing. Latest-filed diluted EPS remains usable for Business Trend, but an integer share-count change lacks enough evidence to confirm a comparable EPS basis; valuation growth therefore stays at 0%. Two-year history is scoreable but carries less confidence than a full-cycle record.
Median gross margin 53.8% over 2y, very stable.
Not enough years of ROIC data to score returns on capital.
Net cash position — no leverage risk.
Owner earnings trend unclear, share count n/a.
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
Price vs. owner-earnings value range
- Owner earnings (normalized)
- $128899
- Value range / share
- $0.08–$0.08
- Conservative high estimate / share
- $0.08
- Recent price
- $0.01
- Price vs. high estimate
- 93% below high estimate
Conservative range under moat-index@2.0.0: low end 11.1×, high end capped at 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
3 years of fundamentals
The business, in plain English
FUNCTIONAL BRANDS INC. booked $6.6M of revenue in FY2025 in the Healthcare sector and kept 52.7% of it as gross profit — a solid-margin business by that measure. After every other cost, 11.5% of each revenue dollar reached the bottom line.
The balance sheet carried $295425 of total debt in FY2025 against $770663 of owner earnings — roughly 0.4 years of owner earnings to retire it all. Balance-Sheet Safety scores it 55/100.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Not disclosed in MEHA’s filings for these years — we don’t estimate it.
Gaps in a line mean that item isn’t in MEHA’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Track record
How FUNCTIONAL BRANDS INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
How to read this: each dot is what the engine would have scored MEHA on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The indexed price path isn't available for this company yet; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the reconstructed history shown, MEHA did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.
Healthcare context
#88 of 736 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #86APT Alpha Pro Tech, Ltd.64.1 out of 100, Narrow moatNarrow moat
- #87GYRE Gyre Therapeutics, Inc.64.1 out of 100, Narrow moatNarrow moat
- #89NRXS Neuraxis, INC63.9 out of 100, Narrow moatNarrow moat
- #90ZBH ZIMMER BIOMET HOLDINGS, INC.63.8 out of 100, Narrow moatNarrow moat
Compare MEHA with its nearest peers →All Healthcare companies on the Index →
Common questions about MEHA
- Does FUNCTIONAL BRANDS INC. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores FUNCTIONAL BRANDS INC. (MEHA) 63.9 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 66, pricing power 90, returns on capital not measurable from the filings, balance-sheet safety 55, capital discipline 44.
- Is MEHA trading below the conservative owner-earnings estimate?
- The owner-earnings value range is $0.08–$0.08 per share. It capitalizes normalized owner earnings at a 9% rate; the low end assumes 0% growth and the high end uses 0% growth, capped at 4% and 18×. Versus a recent price of $0.01, that is 93% below high estimate relative to the high estimate. This is a conservative educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
- How has MEHA's Moat Score changed over time?
- The record logs 5 readings since Jul 18, 2026; the latest reads 63.9 out of 100 (narrow moat). No tier changes on record yet. (A methodology upgrade on Jul 20, 2026 re-based the score; readings across engine versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.